To investigate whether small molecule inhibitors of p300/CBP are effective against MCPyV+ MCC growth, the cell lines PETA and MKL-1 were treated with the panel of p300/CBP-specific HATis used in the studies described above (Figs 2, S1 and S2). The gene discussed is EP300; the disease is Merkel cell skin cancer.